SAN FRANCISCO, March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the
Growth Capitalist (https://growthcapitalist.com/2019/03/nektar-therapeutics-presents-preliminary-immune-activation-safety-and-clinical-activity-data-from-the-ongoing-dose-escalation-stage-of-the-reveal-study-at-2019-asco-sitc-meeting/)
SAN FRANCISCO, March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the